Belgian atopic dermatitis guidelines.

Lapeere, Hilde;Speeckaert, Reinhart;Baeck, Marie;Dezfoulian, Bita;Gutermuth, Jan;et.al.
(2024) Acta Clinica Belgica — Vol. 79, n° 1, p. 62-74 (2024)

Files

2024_Lapeere_Acta_Clin_Belg_Ab.pdf
  • Open Access
  • Adobe PDF
  • 342.19 KB
Download
2024_Lapeere_Acta_Clin_Belg.pdf
  • Restricted Access
  • Adobe PDF
  • 4.11 MB
Request a copy

Details

Authors
  • Lapeere, Hilde
    Author
  • Speeckaert, Reinhart
    Author
  • Baeck, MarieUCLouvain
    Author
  • Dezfoulian, Bita
    Author
  • Gutermuth, Jan
    Author
Show more
Abstract
Atopic dermatitis (AD) is one of the most common, bothersome and difficult to treat skin disorders. Recent introduction of new systemic treatments has revolutionized the management of AD. The goal of this guideline is to provide evidence-based recommendations for the management of patients suffering from atopic dermatitis that easily can be implemented in clinical practice. These recommendations were developed by 11 Belgian AD experts. Comments of all experts on the proposed statements were gathered, followed by an online voting session. The most relevant strategies for the management and treatment of AD in the context of the Belgian health care landscape are discussed. General measures, patient education and adequate topical treatment remain the cornerstones of AD management. For moderate to severe AD, the introduction of biologics and JAK inhibitors show unprecedented efficacy, although currently access is limited to a subgroup of patients meeting the reimbursement criteria.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Lapeere, H., Speeckaert, R., Baeck, M., Dezfoulian, B., Lambert, J., Roquet-Gravy, P.-P., Stockman, A., White, J., Castelijns, F., & Gutermuth, J. (2024). Belgian atopic dermatitis guidelines. Acta Clinica Belgica, 79(1), 62-74. https://doi.org/10.1080/17843286.2023.2285576 (Original work published 2024)